ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific
BMS paid $150m upfront to enter a collaborative development deal for IMA401 with Immatics in 2021.
Cytiva Pipe dream to pipeline WP 3
Pan Cancer T looks to increase T cell durability with next-gen TCR-T
EASD 2024: PolTREG’s T cell therapy shows long-term remission in type 1 diabetes
NeoImmuneTech presents data from Phase Ib trial of CAR-T therapy regimen
IN8bio cuts staff and pipeline to focus on AML cell therapy
ArsenalBio secures $325m to develop cell therapy programmes
RegenxBio touts positive data for rare disease drug RGX-121
FDA grants IND clearance for Galapagos’ non-Hodgkin lymphoma therapy trial
